Novavax opens the week with a chart focus, shares hover around the 200-day line
22.06.2026 - 19:42:44 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-22, 19:40.
Novavax Inc (US66987V1098) begins the new week on NASDAQ trading close to technically relevant levels. The shares most recently changed hands around 9 dollars, while a key moving average sits only slightly higher according to technical data.
What the current chart shows
On NASDAQ, Novavax trades in the high single digits, with recent quotes around 9.07 dollars as of 2026-06-22 09:19:51 Eastern based on consolidated market data. This level compares with a 30 day range roughly between 7.92 and just under 10 dollars, highlighting continued volatility for the biotech name. MarketBeat price overview for NVAX
Technical analysis compiled by Investing.com points to a mixed short term picture. The 200 day moving average for Novavax stands at about 9.528 dollars, moderately above the latest trading area, which this source classifies as a sell signal on that specific long term indicator. At the same time, a set of shorter moving averages, from MA5 to MA200, delivers seven buy markings against five sell ones, underlining how divided chart based signals remain for the stock. Investing.com Novavax technical analysis
Momentum and near term thresholds
The 14 day Relative Strength Index for Novavax sits near 48.5 on Investing.com data, placing the shares almost exactly in the neutral band between overbought and oversold conditions. That RSI reading suggests that, from a pure momentum perspective, neither buyers nor sellers currently dominate the tape in a decisive manner. Investing.com RSI and momentum data
Fibonacci pivot calculations from the same source show a central pivot level for Novavax around 9.188 dollars, very close to the latest spot price. This proximity between last trade and pivot threshold ties in with the neutral RSI and highlights how finely balanced short term trading remains after a year in which the stock has already gained more than 40 percent on some performance measures. StockTitan NVAX performance snapshot
All news and analysis on the Novavax shares
Further background, historical reports and regulatory filings on Novavax can be found in the dedicated topic section and on the company’s own investor relations pages.
How Novavax makes its money
Novavax is a vaccine focused biotechnology company headquartered in Gaithersburg, Maryland, developing protein based vaccines against infectious diseases. Its most prominent product is the Novavax COVID-19 vaccine, now commercialized globally through a partnership with Sanofi, while the pipeline also includes candidates targeting influenza, respiratory syncytial virus, avian flu, shingles and other pathogens. FinancialData company profile for Novavax
Where the stock trades today
The Novavax shares (US66987V1098) trade on NASDAQ at 9.07 dollars as of 2026-06-22 09:19 Eastern, according to consolidated quote data.
Key data on the Novavax shares
- Company: Novavax, Inc.
- ISIN: US66987V1098
- WKN: A2PKMZ
- Ticker: NVAX
- Trading venue: NASDAQ
- Price (as of 2026-06-22, 09:19): 9.07 USD
- Market cap: 1.02 billion USD (as of 2026-06-22)
- Sector / industry: Health Care / Biotechnology
- Index membership: not a member of a major headline index such as S&P 500 or NASDAQ-100
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data are based on sources considered reliable but cannot be guaranteed. Investors should conduct their own research and, where appropriate, consult a licensed financial advisor.
